Health Care and Biotech Stocks Hit Record Highs in 2026 as Investors Flee Pricey Tech

Quick Answer: Health Care And Biotech

Health care and biotechnology stocks climbed to record highs on August 18, 2026, as investors rotated money out of expensive technology and AI names and into defensive sectors. The State Street Health Care Select Sector SPDR ETF, a 44 billion dollar fund of 62 companies, posted a three month total return of 15.6 percent compared with 4.8 percent for the S&P 500. The Vanguard Health Care Index Fund and the iShares Biotechnology ETF also touched records, the latter up 21.1 percent over three months. The move follows strong earnings from AbbVie and UnitedHealth Group, a surge in health care mergers and acquisitions worth nearly 284 billion dollars this year, and growing investor unease about heavy AI capital spending among big technology companies.

Key Takeaways: Health Care And Biotech

• The State Street Health Care Select Sector SPDR ETF, a 44 billion dollar fund tracking 62 companies, reached a record high on August 18, 2026, with a three month total return of 15.6 percent versus 4.8 percent for the S&P 500.

• The Vanguard Health Care Index Fund, a 19 billion dollar fund of 415 stocks, also closed at a record, posting a 16.6 percent three month total return.

• The iShares Biotechnology ETF rose 21.1 percent over the same three month period, also touching an all time high.

• The S&P 500 health care index has climbed 11.2 percent over the past three months, outpacing the broader S&P 500's 6 percent gain, according to Reuters reporting on LSEG data.

• Health care sector merger and acquisition activity has reached nearly 284 billion dollars in 2026, approaching 2025's full year total of 306 billion dollars, according to Dealogic figures cited by Reuters.

• Bank of America's Global Fund Manager Survey found institutional investors moved to a net 32 percent overweight position in health care in July 2026, up sharply from 14 percent in June.

• Eli Lilly and Johnson and Johnson together make up roughly a quarter of the largest health care sector ETFs, meaning their earnings results heavily influence sector wide performance.

• Drugmakers Merck and Moderna posted sharp single day gains after Moderna reported successful phase 3 trial results for a personalized cancer vaccine intended to prevent melanoma recurrence, with Moderna shares up more than 121 percent on the news.

What Is Actually Driving the Rotation

For most of 2026, the stock market story has been dominated by a handful of AI linked technology names. That changed noticeably in mid August. On August 18, health care and biotechnology stocks climbed to all time highs as investors, in the words of CNBC's market coverage, searched for pockets of strength beyond tech. The move was not a one day blip. The State Street Health Care Select Sector SPDR ETF, the largest and most widely held health care fund with 44 billion dollars in assets, posted a three month total return of 15.6 percent, more than triple the S&P 500's 4.8 percent gain over the same stretch. The fund's top holdings, Eli Lilly and Johnson and Johnson, together account for about 26 percent of the portfolio.

The Vanguard Health Care Index Fund, a broader 19 billion dollar fund holding 415 stocks, told a similar story, rising to a record with a 16.6 percent three month total return. The iShares Biotechnology ETF outpaced both, climbing 21.1 percent over three months as smaller, higher risk biotech names participated in the rally alongside large pharmaceutical companies.

Reuters reporting on the broader trend, based on LSEG Lipper fund flow data, found that roughly 50 U.S. listed health care funds attracted 2.44 billion dollars in new money in July 2026 alone, extending a nearly 1.5 billion dollar inflow in June and reversing three straight months of investors pulling money out of the sector. J.P. Morgan strategists, led by Dubravko Lakos Bujas, described health care as offering durable growth and attractive valuation at a time when many investors remain heavily concentrated in the AI theme, a dynamic that has left the sector looking relatively cheap compared with its own history and compared with technology stocks.

The Earnings and Dealmaking Behind the Move

Sentiment shifts do not happen in a vacuum. Drugmaker AbbVie topped second quarter profit estimates in its most recent earnings report, and health insurer UnitedHealth Group beat profit expectations while raising its full year 2026 forecast, according to Reuters. Those results helped reverse what LSEG's head of earnings research, Tajinder Dhillon, described as a 16.7 percent earnings contraction for S&P 500 health care companies in the second quarter of 2026, with double digit earnings growth now expected from the fourth quarter of 2026 through the end of 2027.

Dealmaking has added further fuel. Health care merger and acquisition activity has reached nearly 284 billion dollars so far in 2026, according to Dealogic figures cited by Reuters, closing in on 2025's full year total of 306 billion dollars and already topping every other year since 2021. A separate, sharper catalyst arrived on August 19, when Merck and Moderna both surged after Moderna reported successful phase 3 trial results for an experimental personalized cancer vaccine designed to prevent the recurrence of melanoma. Moderna shares jumped more than 121 percent on the news, while Merck, a partner on the vaccine program, rose about 10 percent, giving the entire sector an additional boost just as the broader rotation was already underway.

Is This Rotation Built to Last

Not every analyst is convinced the move has staying power. Some strategists have drawn comparisons to a similar rotation away from tech in 2022 that ultimately faded once investor confidence in the tech rally returned. What is different this time, according to Mark Hackett, chief market strategist at Nationwide, is that the S&P 500 itself remains at record highs even as money flows into previously unloved sectors, which he argues tends to be a more sustainable pattern than a rotation driven by fear of an outright market decline.

Bank of America's Global Fund Manager Survey lends some support to that view. The July 2026 survey found institutional investors had moved to a net 32 percent overweight position in health care, more than double the 14 percent overweight reading from just one month earlier, suggesting professional money managers are making a deliberate allocation shift rather than a short lived reaction to a single earnings season.

Key Health Care Funds at a Glance

Figures reflect data reported as of August 18, 2026, and will change over time.

What Health Care And Biotech Means for Your Money

If you have been entirely concentrated in AI and technology names, the health care rotation is worth watching as a reminder that sector leadership can shift faster than expected, particularly once valuations in a hot sector stretch and cheaper alternatives elsewhere start to look attractive by comparison.

Readers who want a fuller picture of what is happening on the other side of this rotation should see our coverage of the global chip selloff deepening into a bear market, which explains the technology side of this story.

For context on how AI spending concerns are reshaping the broader market, our piece on the AI stock boom of 2026 is a useful companion read.

If dividend paying, income generating sectors like health care appeal to you as a portfolio anchor, our guide to the best dividend ETFs for passive income covers similar defensive strategies outside health care specifically.

And for readers tracking how large institutional investors are positioning across sectors, see our coverage of Berkshire Hathaway's recent moves in its Alphabet stake.

Key Takeaways Recap: Health Care And Biotech

Health care and biotechnology stocks reached record highs in mid August 2026 as investors rotated out of expensive technology and AI names, with major sector ETFs posting three month returns between 15.6 and 21.1 percent, far outpacing the broader S&P 500's 4.8 percent gain. The move is supported by strong earnings from AbbVie and UnitedHealth Group, nearly 284 billion dollars in sector dealmaking, and a sharp increase in institutional overweight positioning according to Bank of America's fund manager survey. A late breaking catalyst, Moderna's successful cancer vaccine trial results, added further momentum on August 19. Whether the rotation holds depends on continued earnings strength and whether investor confidence in AI spending returns.

Financial Disclaimer & Regulatory Disclosure

This article is for informational purposes only and does not constitute investment advice. Stock and fund performance discussed reflects data as of the dates cited and can change quickly. Consult a qualified financial advisor before making investment decisions.

📊 Related Tools: Use our ROI & Annualized Return Calculator to measure your historical investment returns and annual compound growth rate across volatile market cycles. Use our Portfolio Visualizer & Asset Allocation Tool to backtest diversified multi-asset portfolios and run Monte Carlo risk simulations.